Ocean Biomediacal, Inc. · OTC:OCEA
Ocean Biomediacal — Ocean Biomedical — Investor Presentation (March 2023)
35 slides from Ocean Biomediacal's investor presentation, Mar 17, 2023
Slide 1: Ocean Biomedical Company Overview
id OCEAN BIOMEDICAL e =a : SS, oH we NASDAQ: Ocean Biomedical ; Company Overview “ March 16, 2023 ~ OCEA ° Empowering Great Science. Accelerating Translation. Changing Medicine.
Slide 2: Forward-Looking Statements
Forward-Looking Statements ‘The information included herein and in any oral statements made in connection herewith include “Terward-looking statements" within the meaning ofthe “safe harbor" provisions ofthe United States Private Securities Litigation Reform Act of 1995. Forward-looking statements m
Slide 3: Innovative business model bridges the bench-to-bedside gap
Innovative business model bridges the ‘bench-to-bedside’ gap by accelerating the commercialization of innovative assets contained within research universities and medical centers Initial core portfolio in oncology, fibrosis, and infectious disease, all based on new target discoveries enabling first-
Slide 4: Management team
i OCEAN Elizabeth Ng CEO, Director Proven biotechnology strategic leader. Bioelectre Devices, BioMarn Pharmaceutical, Merck & Co, Gilead Sciences, Strategic Decisions Group. MBA Stanford, 8S RAT. Dr. Jack A. Elias Co-Founder, Chair of SAB Dean Emeritus of Medicine, Brown; Chet of Pulmonary & Cees! C
Slide 5: Board of directors
OCEAN Dr. Michelle Berrey President RO and CMO, Intercept pac President, C80, NO, (Chimes nd CMO, Parmazzt ne (6S: Drctor a amnes Frenthoos Federation of mete; SAB 3 VIV/GSK NEBtech Si. Fellow, IO Medene, Uf Washington MD. Colege of Geos, MPH... Emory Unversity Governor! ‘Owens ‘eto & calrof or, Gow
Slide 6: Ocean Biomedical is not a company but rather companies in one
Ocean Biomedical is not 1 company but rather 3 companies in one — plus our business model ensures continual growth OCEAN BIOMEDICAL Parent Operating Company + Sub co. oversight + Operational efficiency + Nimble drug development OCEAN BIOMEDICAL PLUS: Current Indications & Drug Candidates* Competitiv
Slide 7: Bridging the gap from IND enablement to commercial launch
IND Enablement Clinical Development. FDA Approval Commercial Launch 26,000/year invention disclosures* Patients with unmet medical needs $71B/year research expenditures* Pharma companies with dry pipelines Few cross the gap and reach the market * Driven by the goal of getting drugs to patients; Work
Slide 8: Our business model and strategy are designed to benefit patients and create value
Our business model and strategy are designed to benefit patients and efficiently create value for our stakeholders and partners Access to innovations Conse OCEAN BIOMEDICAL ane universities and medical . Pete rontere Parent Operating Company (NASDAQ: OCEA) Portfolio oversight and operational efficie
Slide 9: Approach: partner of choice for universities and medical centers
Approach: designed to make Ocean the ‘partner of choice’ for universities, medical centers and their researchers Typical Options for Institutions/ Researchers Challenges — Pharma prefers later-stage assets Vv Development-stage agnostic ad License — Economic upside is limited V Inventors and their in
Slide 10: Ocean's initial portfolio addresses high-value and high-impact indications
Ocean’s initial portfolio addresses high-value and high-impact indications Our main programs in oncology, fibrosis, and infectious diseases are all nearing IND application, are licensed from Brown University and RI Hospital, and have been developed through past and on-going grants totaling $123.9 mi
Slide 11: Ocean's current pipeline presents multiple shots on goal
Ocean’s current pipeline presents multiple ‘shots on goal’ Pipeline leverages research university/medical center partnerships to bring diverse and innovative candidates through preclinical studies ooxass a ons sce ve — ialsPG NScLe oes 2 oncseey | occai0 race aero 2 coxsos | SRE Syria cus vas i secu
Slide 12: Core expertise and capabilities leveraging external resources
Ocean has core expertise/capabilities and leverages external resources OCEAN BIOMEDICAL Core operating team skilled at selecting assets and driving them through development + ies & capacity to accelerate development of multiple programs ws Drug Development Advisors Execution Advisory Services CROs /
Slide 13: Disciplined criteria-driven process to select new programs
We use a disciplined criteria-driven process to identify, assess and select new programs and indications — and to continually review existing ones Science Scientific Rationale / Model Predictability + Does it make scientific sense? Unmet Need: + Willit profoundly benefit patients? | functional Oppor
Slide 14: Ocean Biomedical portfolio and comparators
jnancin Ocean Biomedical Portfolio Oncology - NSCLC and GBM Plus: additional bispecific mAbs with immune checkpoint inhibitors & extension to other cancers Fibrosis — IPF and HPS Plus: extension to other fibrotic diseases such as scleroderma and NASH Infectious disease - Malaria Plus: discovery plat
Slide 15: Valuations of peer group companies
Valuations of peer group companies, in millions at market closing on Thursday, Mar 9, 2023* $1,283 $1,215 $1,212 $1,150" $382 $368 $340 $331 $276 $196 $187 $177 somes TANGA incusse ANZ Siditinn (0, Qocean : CAL WR gBiyr Orden DICE ances ARCLE TYRA egccurass SPTANGO Serato lf mune OMEGA’ Girncee OCEA
Slide 16: M&A transactions in IPF and oncology
M&A transactions in IPF and oncology highlight Ocean’s potential for exceptional value IPF Oncology {kinase Inhibitors) OCEAN 8) Roche ~Intermune, 2014* Phill $8.38" Biogen — Stromedix, 2012 Phil §563M* Samumed — United, 2018 Phi $350M” Roche ~ Promedior, 2019 Phil $1,488 Lilly ~ Loxo, 2019 Approved
Slide 17: Our valuation is attractive compared to our peer group
* Our valuation is extremely attractive compared to our peer group — especially considering that Ocean is the parent company of 3 biotech companies (oncology, fibrosis, infectious diseases). * Ocean Biomedical has no legacy preferred shareholders who often over-inflate valuations. * Ocean’s multi-as
Slide 18: Success of similar portfolio R&D approaches
The success of similar ‘portfo business model io R&D’ approaches supports the potential of Ocean’s Comparable Example Approach? Ocean Business Model Differentiation pad Ree pridgebio cullnan ONCOLOGY 6 BLAVATNIK Fund Ay sximevaioe Yale Founded 2015 Focused primarily on single-gene rare diseases “Cre
Slide 19: Sustainable growth strategy is opportunistic across indications
Sustainable growth strategy is opportunistic with regards to indications, diseases, and therapeutic areas New programs from SREP E Ne Additional indications, diseases, and therapeutic areas relationships with * Selective process with stringent criteria that allows identification of valuable assets /
Slide 20: Oncology (NSCLC, GBM)
Oncology (NSCLC, GBM)
Slide 21: NSCLC and GBM have significant unmet needs
Non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM) have significan unmet needs Non-small cell lung cancer (NSCLC) Leading cause of cancer death and second most diagnosed cancer in the US + Affects approximately 460,000 people in the U.S. * Accounts for about 85% of new lung cancers
Slide 22: Science: Chitinase 3-like-1 (Chi3L1)
Science Ocean’s Innovation Chitinase 3-like-1 (Chi3L1) Novel target & pathway discovery: * Dysregulated and plays a critical role in the pathogenesis of primary and metastatic lung cancer. + Plays a synergistic effect with checkpoint inhibitors such as PD1 Neutralizing antibodies against Chi3L1 have
Slide 23: Key takeaways about our mAb candidates in oncology
Key takeaways about our humanized monoclonal antibody (mAb) therapeutic candidates in oncology Scientifically Compelling * Novel target: chi3I1 is a master regulator of many visceral tumors regardless of genetic mutations * First-in-class: proprietary mono-specific and bispecific mAbs are first to t
Slide 24: Fibrosis (IPF, HPS)
Fibrosis (IPF, HPS)
Slide 25: Fibrosis affects most organs and tissues
Fibrosis affects most organs and tissues and is a leading cause of morbidity and mortality @ ‘Asthma Pulmonary arterial HIN NASH eve PF Hermansky-Pudlak Syndrome Idiopathic portal TW i (eta poo pune liver ‘Alcoholic Uver Disease Primary sclerosing cholangitis 38 Congenital hepatic fibrosis Primary b
Slide 26: IPF and HPS have significant unmet needs
Idiopathic pulmonary fibrosis (IPF) & Hermanksy-Pudlak Syndrome (HPS) have significant unmet needs Idiopathic pulmonary fibrosis (IPF) Progressive disease that results in irreversible loss of lung function with high morbidity and mortality rates + IPF prevalence in the US has been reported to range
Slide 27: Science: Chitinase (Chit1)
Science Ocean’s Innovation Chitinase 1 (Chit1) Novel target & pathway discovery: Key regulator of tissue damage and remodeling. + Critical biomarker and therapeutic target in SSc-ILD (Scleroderma-associated interstitial ung disease) + Plays role in bleomycin- and IL-13 induced pulmonary fibrosis + E
Slide 28: Key takeaways about our small molecule candidate in fibrosis
Key takeaways about our small molecule therapeutic candidate in fibrosis Scientifically Compelling + Novel target: chit1 is key regulator of tissue damage and remodeling + Potential for disease-modifying activity: 85-90% reduction in collagen accumulation in 4 pulmonary fibrosis animal models * Well
Slide 29: Infectious Diseases (Malaria)
Slide 30: The Need: massive unmet public health need in malaria
~3 billion At risk of infection annually worldwide 200-300 million Infected annually worldwide 500,000+ Children under age 5 killed annually OCEAN The Need: Massive unmet public health need with no effective prophylactic vaccine Despite the recent hype and a $18 grant from Gates, Mosquirix has serio
Slide 31: Science
Science Caused by parasites and transmitted through the bites of infected female Anopheles mosquitoes Five parasite species cause malaria in humans, the deadliest of which is Plasmodium falciparum (P. falciparum) Malaria caused by Plasmodium falciparum remains the leading single-agent killer of chil
Slide 32: Proprietary drug discovery platform yields vaccine and therapeutic candidates for malaria
Proprietary drug discovery platform for infectious diseases has yielded promising vaccine and therapeutic candidates for mala Mouse antibodies toPYGARP kil hee diferent strain of __Recombinant poten irmuniation of nonhuman erate? > foleporum by 94-29% primates wth PFOARP © NoSerum @ Pre-Immune oe s
Slide 33: Key takeaways about our malaria vaccine and therapeutic candidates
Key takeaways about our vaccine and therapeutic candidates for malaria — and about our infectious disease target discovery platform Scientifically Compelling + Novel targets: PfGARP and PfSEA-1 are critical for parasite survival + Proof of Concept: 100% killing of malaria parasites in in-vitro assay
Slide 34: Executive Summary
Executive Summary Accessing innovations, developing them into high-value, clinical assets, and unleashing their value Sourcing best-of-breed academic innovations to develop first-in-class biopharma products + Advantaged access to university & medical center inventions - maximizing their economic ups
Slide 35: Thank you
Ocean Biomedical — Investor Presentation (March 2023) on 6ix